Navigation Links
Incline Therapeutics to Present at the Cowen and Company 32nd Annual Health Care Conference
Date:3/1/2012

REDWOOD CITY, Calif., March 1, 2012 /PRNewswire/ -- Incline Therapeutics, Inc., a hospital-focused specialty pharmaceutical company, announced today that Alan Levy, PhD, Chief Executive Officer, and David Socks, President and Chief Operating Officer, will present at the Cowen and Company 32nd Annual Health Care Conference on Tuesday, March 6, 2012 at 10:00a.m. Eastern Time at the Boston Marriott Copley Place.

About Incline Therapeutics, Inc.
Incline Therapeutics is a hospital-focused specialty pharmaceutical company focused on the development of IONSYS (fentanyl iontophoretic transdermal system), a compact, disposable, needleless patient-controlled system for the short-term management of acute postoperative pain in adult patients requiring opioid analgesia during hospitalization.  IONSYS has completed Phase III development and was previously approved in the United States and Europe.  Prior to marketing IONSYS, Incline must seek approval of a supplement New Drug Application (sNDA) in the United States and a Marketing Authorization Application (MAA) in Europe.  Incline is financed by leading life science venture capital firms and led by a management team with significant pharmaceutical and medical device industry experience.  The company is based in Redwood City, California.

Incline™ and IONSYS™ are trademarks of Incline Therapeutics, Inc.


'/>"/>
SOURCE Incline Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial
2. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
3. Orexigen Therapeutics to Present at Upcoming Conferences
4. ResearchMoz: Nanotech Enabled Drug Delivery Therapeutics Market Will be $136 Billion by the Year 2021: Nanotechnology in Drug Delivery: Global Markets
5. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
6. Healthpoint Biotherapeutics to Present at 30th Annual J.P. Morgan Healthcare Conference
7. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
8. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
9. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
10. Amsterdam Molecular Therapeutics Announces € 2.5 Million Equity Raise
11. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... SHANGHAI , Jan. 19, 2017 /PRNewswire -- ... medical device open-access capability and technology platform, today ... a leading biology focused preclinical drug discovery contract ... Biosciences will become a wholly-owned subsidiary of WuXi, ... core competences and providing greater services. The acquisition ...
(Date:1/19/2017)... 2017  ArmaGen, Inc., today announced that it ... chief executive officer, as well as a member ... ArmaGen more than 17 years of executive management ... biotherapeutics and pharmaceuticals. "Mathias is ... and skillset necessary to lead ArmaGen to its ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... spanning the full spectrum of drug and device development, and Prism Clinical ... companies and clinicians, today announced Verified Clinical Trials (VCT) has been ...
(Date:1/18/2017)... ... 2017 , ... Opal Kelly, a leading producer of powerful ... the ZEM5310 USB 3.0 FPGA Module, combining a SuperSpeed USB 3.0 interface and ... suitable for prototyping, testing, and production-ready integration. The ZEM5310 USB interface delivers real-world ...
Breaking Biology Technology:
(Date:1/6/2017)... NEWARK, Calif. , Jan. 5, 2017  Delta ... introduced its iris scanning technology for automotive at CES® ... GNTX ) to demonstrate the use of ... to identify and authenticate the driver in a car, ... automobiles during the driving experience. Delta ID ...
(Date:12/22/2016)... 2016  As part of its longstanding mission to improve ... company, recently released its latest children,s book, titled ... on the topics of inheritance and variation of traits that ... in elementary school classrooms in the US. ... Ariana Killoran , whose previous book with 23andMe, ...
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016 /PRNewswire/ ... que permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado que ... de tumor en 2017, con múltiples sitios previstos a lo largo ... ... en el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que ...
Breaking Biology News(10 mins):